Elevated DISC1 transcript levels in pbmcs during acute psychosis in patients with schizophrenia

Translational Biomedicine

Volumn 2, Issue 1, 2011, Pages

  Olincy, Ann ^a   House, Robert ^b   Gao, Bifeng ^c   Recksiek, Peter ^a   Phang, Tzu Lip ^c   Sullivan, Bernadette ^a   Hollis, Jeff P ^a   Hopkins, Janet ^a   Shade, Ted ^c   Edwards, Michael G ^c   Vianzon, Ruby ^a   Griffiths, Cory ^a   Ceilley, John ^b   Helfrich, Roger W ^b   Ritvo, Jonathan ^b   Weis, Erica ^b   Weiss, David ^b   Gault, Judith ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; BENZATROPINE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; FLUPHENAZINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RNA; VALPROIC ACID;

ACUTE PSYCHOSIS; ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; GENE EXPRESSION PROFILING; HOSPITALIZATION; HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITIVE SYNDROME; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; TREATMENT RESPONSE;

EID: 84859628493     PISSN: None     EISSN: 21720479     Source Type: Journal    
DOI: 10.3823/421     Document Type: Article

References (37)

1. Harrison, G., K. Hopper, T. Craig, E. Laska, C. Siegel, et al., (2001) Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 178: 506-17.
2. Weiden, P.J. and M. Olfson, (1995) Cost of relapse in schizophrenia. Schizophr Bull. 21;3: 419-29.
3. Meagher, D.a.M., M., (2003) Sub-optimal prescribing in an adult community mental health service: prevalence and determinants. Psychiatr. Bull. 27: 266-270.
4. Csernansky, J.G., R. Mahmoud, and R. Brenner, (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 346;1: 16-22.
5. Ray, W.A., C.P. Chung, K.T. Murray, K. Hall, and C.M. Stein, (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 360;3: 225-35.
6. Swartz, M.S., D.O. Perkins, T.S. Stroup, S.M. Davis, G. Capuano, et al., (2007) Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 164;3: 428-36.
7. Jones, P.B., T.R. Barnes, L. Davies, G. Dunn, H. Lloyd, et al., (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 63;10: 1079-87.
8. Leucht, S., C. Corves, D. Arbter, R.R. Engel, C. Li, et al., (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 373;9657: 31-41.
9. Farde, L., A.L. Nordstrom, F.A. Wiesel, S. Pauli, C. Halldin, et al., (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 49;7: 538-44.
10. Kapur, S., R. Zipursky, C. Jones, G. Remington, and S. Houle, (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia. Am J Psychiatry. 157;4: 514-20.
11. Zvara, A., G. Szekeres, Z. Janka, J.Z. Kelemen, C. Cimmer, et al., (2005) Over-expression of dopamine D2 receptor and inwardly rectifying potassium channel genes in drug-naive schizophrenic peripheral blood lymphocytes as potential diagnostic markers. Dis Markers. 21;2: 61-9.
12. Tsuang, M.T., N. Nossova, T. Yager, M.M. Tsuang, S.C. Guo, et al., (2005) Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 133;1: 1-5.
13. Fitzgerald, P.B., S. Kapur, G. Remington, P. Roy, and R.B. Zipursky, (2000) Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl). 149;1: 1-5.
14. Blackwood, D.H., A. Fordyce, M.T. Walker, D.M. St Clair, D.J. Porteous, et al., (2001) Schizophrenia and affective disorders--cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet. 69;2: 428-33.
15. Green, E.K., N. Norton, T. Peirce, D. Grozeva, G. Kirov, et al., (2006) Evidence that a DISC1 frame-shift deletion associated with psychosis in a single family may not be a pathogenic mutation. Mol Psychiatry. 11;9: 798-9.
16. Sachs, N.A., A. Sawa, S.E. Holmes, C.A. Ross, L.E. DeLisi, et al., (2005) A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. Mol Psychiatry. 10;8: 758-64.
17. Allen, N.C., S. Bagade, M.B. McQueen, J.P. Ioannidis, F.K. Kavvoura, et al., (2008) Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 40;7: 827-34.
18. Khoury, M.J., L. Bertram, P. Boffetta, A.S. Butterworth, S.J. Chanock, et al., (2009) Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol. 170;3: 269-79.
19. Harrison, P.J. and D.R. Weinberger, (2004) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry.
20. Hattori, T., K. Baba, S. Matsuzaki, A. Honda, K. Miyoshi, et al., (2007) A novel DISC1-interacting partner DISC1-Binding Zinc-finger protein: implication in the modulation of DISC1-dependent neurite outgrowth. Mol Psychiatry. 12;4: 398-407.
21. Assmann, E.M., M.R. Alborghetti, M.E. Camargo, and J. Kobarg, (2006) FEZ1 dimerization and interaction with transcription regulatory proteins involves its coiled-coil region. J Biol Chem. 281;15: 9869-81.
22. Morris, J.A., G. Kandpal, L. Ma, and C.P. Austin, (2003) DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Hum Mol Genet. 12;13: 1591-608.
23. Brandon, N.J., E.J. Handford, I. Schurov, J.C. Rain, M. Pelling, et al., (2004) Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders. Mol Cell Neurosci. 25;1: 42-55.
24. Mao, Y., X. Ge, C.L. Frank, J.M. Madison, A.N. Koehler, et al., (2009) Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell. 136;6: 1017-31.
25. Numata, S., S. Ueno, J. Iga, H. Song, M. Nakataki, et al., (2008) Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the Japanese population. J Psychiatr Res. 43;1: 7-12.
26. Beaulieu, J.M., R.R. Gainetdinov, and M.G. Caron, (2009) Akt/ GSK3 Signaling in the Action of Psychotropic Drugs. Annu Rev Pharmacol Toxicol. 49: 327-47.
27. Emamian, E.S., D. Hall, M.J. Birnbaum, M. Karayiorgou, and J.A. Gogos, (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 36;2: 131-7.
28. Kang, U.G., M.S. Seo, M.S. Roh, Y. Kim, S.C. Yoon, et al., (2004) The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett. 560;1-3: 115-9.
29. Andreasen, N.C., M. Pressler, P. Nopoulos, D. Miller, and B.C. Ho, (2010) Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 67;3: 255-62.
30. First MB, S.R., Gibbon M, Williams JBW, Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0, 4/97 revision), ed. B.R. Department. 1997, New York: New York State Psychiatric Institute.
31. Marshall, O.J., (2004) PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. Bioinformatics. 20;15: 2471-2.
32. Nakata, K., B.K. Lipska, T.M. Hyde, T. Ye, E.N. Newburn, et al., (2009) DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms. Proc Natl Acad Sci U S A. 106;37: 15873-8.
33. Kapur, S., R. Zipursky, P. Roy, C. Jones, G. Remington, et al., (1997) The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl). 131;2: 148-52.
34. Beaulieu, J.M., T.D. Sotnikova, W.D. Yao, L. Kockeritz, J.R. Woodgett, et al., (2004) Lithium antagonizes dopaminedependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A. 101;14: 5099-104.
35. Snider, S.R. and O. Kuchel, (1983) Dopamine: an important neurohormone of the sympathoadrenal system. Significance of increased peripheral dopamine release for the human stress response and hypertension. Endocr Rev. 4;3: 291-309.
36. Nakano, K., T. Higashi, R. Takagi, K. Hashimoto, Y. Tanaka, et al., (2009) Dopamine released by dendritic cells polarizes Th2 differentiation. Int Immunol. 21;6: 645-54.
37. Seeman, P., (2007) Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors. Synapse. 61;12: 1013-8.